Affiliation:
1. N. N. Blokhin National Medical Research Center of Oncology
2. N. N. Blokhin National Medical Research Center of Oncology; I. M. Sechenov First Moscow State Medical University (Sechenov University)
3. Pirogov Russian National Research Medical University
4. City Clinical Oncological Hospital № 1
Abstract
Background: Recurrent ovarian cancer (OC) patients with platinum‑free interval (PFI) < 6 mo. are usually considered platinum‑resistant and treated with non‑platinum based chemotherapy. There is a lack of evidence to compare various non‑platinum therapeutic options in patients with platinum‑resistant ovarian cancer (PROC). We conducted meta‑analysis to assess efficacy of various therapeutic options in PROC patients. This article aimed to compare non‑platinum therapeutic regimens.Methods: We queried the PubMed database for full‑text articles and abstracts on the treatment of PROC patients (01/01/2000–01/06/2019 timeframe). Inclusion criteria were: 1) epithelial ovarian cancer; 2) recurrent disease ≤ 6 mo. after platinum‑based chemotherapy; 3) standard therapy with platinum‑ or non‑platinum agents; 4) no targeted therapy, investigational agents or non‑platinum doublets; 5) reported response rate (RR) and assessment criteria. Proportion meta‑analysis (random‑effect model) and beta‑regression were conducted to assess efficacy of various options. Statistical analysis was dose with meta and betareg packages of R software.Results: We identified 7156 articles and screened them for title and abstract, 157 studies were left for further analysis. Efficacy of non‑platinum‑ and platinum‑based therapy was assessed in 113 (n = 5272) and 44 (n = 1055) trials respectively, only the latter were included in this analysis. In meta‑proportion random‑ effect model RR among patients treated with taxanes, etoposide, doxorubicin/PLD, topotecan and gemcitabine were 27 % (95 % CI 0.21–0.34), 19 % (95 % ДИ 0.13–0.27), 15 % (95 % CI 0.11–0.19), 13 % (95 % CI 0.10–0.18) and 10 % (95 % CI 0.07–0.14), respectively. Multiple beta‑regression model accounting for response assessment method, number of prior therapy lines and other factors confirmed the results.Conclusions: Taxanes monotherapy may be the most effective therapeutic option for patients who are not candidates for platinum‑based chemotherapy.
Publisher
Russian Society of Clinical Oncology
Subject
General Agricultural and Biological Sciences
Reference97 articles.
1. Kaprin AD, Starinskii VV, Shakhzadova AO. Zlokachestvennye novoobrazovaniya v Rossii v 2019 godu: zabolevaemost' i smertnost' godu – M.: MNIOM im. P. A. Gertsena – filial FGBU «NMITs radiologii» Minzdrava Rossii, 2020. – ill. – 252 s. ISBN 978-5-85502‑260-5.
2. Tyulyandina AS, Kolomiets LA, Morkhov KYu, et al. Prakticheskie rekomendatsii po lekarstvennomu lecheniyu raka yaichnikov, pervichnogo raka bryushiny i raka matochnykh trub. Zlokachestvennye Opukholi. 2021;11 (3s2):158-171.
3. Elektronnyi resurs: NCCN Clinical practice guidelines-Ovarian cancer, 2022. Poslednii dostup: 01.02.2022. Dostupno onlain na veb-stranitse: https://www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
4. Therasse P, Arbuck SG, Eisenhauer EA, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst. 2000;92 (3):12.
5. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1—Update and clarification: From the RECIST committee. Eur J Cancer. 2016;62:132‑137. doi:10.1016/j.ejca.2016.03.081